A Phase Ib Study to Evaluate the Safety and Efficacy of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma
Latest Information Update: 17 Mar 2023
At a glance
- Drugs IBI 318 (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Innovent Biologics
- 14 Mar 2023 Status changed from not yet recruiting to discontinued.
- 24 Nov 2020 New trial record
- 22 Nov 2020 Planned initiation date changed from 20 Nov 2020 to 26 Nov 2020.